Stock Track | Embecta Corp. Surges 5.25% Pre-Market on Strong Q2 Earnings Beat

Stock Track

May 09, 2025

Embecta Corp. (NASDAQ: EMBC) shares soared 5.25% in pre-market trading on Friday following the release of its second-quarter fiscal 2025 financial results, which significantly exceeded analyst expectations.

The diabetes care company reported adjusted earnings per share of $0.70, surpassing the analyst consensus estimate of $0.53 by 32.08%. This represents a 4.48% increase from the same period last year. Embecta's quarterly revenue came in at $259 million, beating the analyst estimate of $253.94 million by 1.99%, despite a 9.82% decrease from the previous year.

Investors were particularly impressed by Embecta's profitability metrics. The company reported an adjusted EBITDA of $97.1 million, significantly higher than the IBES estimate of $83.7 million. Additionally, adjusted operating income reached $81.4 million, compared to the expected $66.6 million. These strong results, coupled with the company's maintenance of its full-year adjusted earnings per share guidance despite lowered revenue expectations, have boosted investor confidence in Embecta's ability to navigate challenges in the current market environment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1111791235"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111791235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111791235?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111791235","market":"us","top_or_hot":-1,"title":"Stock Track | Embecta Corp. Surges 5.25% Pre-Market on Strong Q2 Earnings Beat","media":"Stock Track","content":"<p>Embecta Corp. (NASDAQ: EMBC) shares soared 5.25% in pre-market trading on Friday following the release of its second-quarter fiscal 2025 financial results, which significantly exceeded analyst expectations.</p>\n\n<p>The diabetes care company reported adjusted earnings per share of $0.70, surpassing the analyst consensus estimate of $0.53 by 32.08%. This represents a 4.48% increase from the same period last year. Embecta's quarterly revenue came in at $259 million, beating the analyst estimate of $253.94 million by 1.99%, despite a 9.82% decrease from the previous year.</p>\n\n<p>Investors were particularly impressed by Embecta's profitability metrics. The company reported an adjusted EBITDA of $97.1 million, significantly higher than the IBES estimate of $83.7 million. Additionally, adjusted operating income reached $81.4 million, compared to the expected $66.6 million. These strong results, coupled with the company's maintenance of its full-year adjusted earnings per share guidance despite lowered revenue expectations, have boosted investor confidence in Embecta's ability to navigate challenges in the current market environment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Embecta Corp. Surges 5.25% Pre-Market on Strong Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Embecta Corp. Surges 5.25% Pre-Market on Strong Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-09 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Embecta Corp. (NASDAQ: EMBC) shares soared 5.25% in pre-market trading on Friday following the release of its second-quarter fiscal 2025 financial results, which significantly exceeded analyst expectations.</p>\n\n<p>The diabetes care company reported adjusted earnings per share of $0.70, surpassing the analyst consensus estimate of $0.53 by 32.08%. This represents a 4.48% increase from the same period last year. Embecta's quarterly revenue came in at $259 million, beating the analyst estimate of $253.94 million by 1.99%, despite a 9.82% decrease from the previous year.</p>\n\n<p>Investors were particularly impressed by Embecta's profitability metrics. The company reported an adjusted EBITDA of $97.1 million, significantly higher than the IBES estimate of $83.7 million. Additionally, adjusted operating income reached $81.4 million, compared to the expected $66.6 million. These strong results, coupled with the company's maintenance of its full-year adjusted earnings per share guidance despite lowered revenue expectations, have boosted investor confidence in Embecta's ability to navigate challenges in the current market environment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMBC","symbol_name":"Embecta Corp.","start_time":0,"source_url":"","article_id":"1111791235","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111791235","pubTimestamp":1746792163,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Embecta Corp.  shares soared 5.25% in pre-market trading on Friday following the release of its second-quarter fiscal 2025 financial results, which significantly exceeded analyst expectations.The diabetes care company reported adjusted earnings per share of $0.70, surpassing the analyst consensus estimate of $0.53 by 32.08%. This represents a 4.48% increase from the same period last year. Embecta's quarterly revenue came in at $259 million, beating the analyst estimate of $253.94 million by 1.99","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMBC":"Embecta Corp."},"translate_title":"Embecta Corp.第二季度盈利强劲，盘前股价飙升5.25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMBC":1},"content_text":"Embecta Corp. (NASDAQ: EMBC) shares soared 5.25% in pre-market trading on Friday following the release of its second-quarter fiscal 2025 financial results, which significantly exceeded analyst expectations.\nThe diabetes care company reported adjusted earnings per share of $0.70, surpassing the analyst consensus estimate of $0.53 by 32.08%. This represents a 4.48% increase from the same period last year. Embecta's quarterly revenue came in at $259 million, beating the analyst estimate of $253.94 million by 1.99%, despite a 9.82% decrease from the previous year.\nInvestors were particularly impressed by Embecta's profitability metrics. The company reported an adjusted EBITDA of $97.1 million, significantly higher than the IBES estimate of $83.7 million. Additionally, adjusted operating income reached $81.4 million, compared to the expected $66.6 million. These strong results, coupled with the company's maintenance of its full-year adjusted earnings per share guidance despite lowered revenue expectations, have boosted investor confidence in Embecta's ability to navigate challenges in the current market environment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}